Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31694805 | 0.81 | ACE (0.63) | ACEMAPK1ATMPOLBGAA | |
| SCHEMBL29050322 | 0.81 | ACE (0.63) | ACEMAPK1ATMPOLBGAA | |
| SCHEMBL25253542 | 0.76 | ACE (0.41) | ACEATM | |
| SCHEMBL25290388 | 0.76 | ACE (0.41) | ACEATM | |
| SCHEMBL11364967 | 0.74 | MAPK1 (0.42) | MAPK1POLBNOTUMELANE | |
| SCHEMBL11735474 | 0.72 | BRD4 (0.38) | MAPK1ATMPOLBNOTUM | |
| SCHEMBL1249829 | 0.68 | ACE (0.39) | ACEMAPK1ATMPOLBGAA | |
| SCHEMBL1249826 | 0.68 | ACE (0.39) | ACEMAPK1ATMPOLBGAA | |
| SCHEMBL1249827 | 0.68 | ACE (0.39) | ACEMAPK1ATMPOLBGAA | |
| SCHEMBL1249824 | 0.68 | ACE (0.39) | ACEMAPK1ATMPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109698-A1 | MALT-1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2026-04-23 | — | — | US | disclosed |
| US-20250051327-A1 | MALT-1 MODULATORS | RECURSION PHARMACEUTICALS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4247492-A1 | MALT-1 MODULATORS | Exscientia Al Limited (GB) | 2023-09-27 | — | — | EP | disclosed |
| CN-116528857-A | MALT-1 modulators | 艾克斯赛安西娅人工智能有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022106857-A1 | MALT-1 MODULATORS | Exscientia Limited (GB) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051327-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL9 | ACE 3649/4885MAPK1 963/4885ATM 2751/4885 |
| US-20260109698-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL3 | ACE 4028/4885MAPK1 2771/4885ATM 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.